INTRODUCTION
============

Accurate prognostic information in palliative settings is necessary for patients to make decisions and set goals and priorities. Palliative care physicians should carefully provide patients and their families with the most accurate prognostic information in order to improve end-of-life care. A number of prognostic factors in terminal cancer patients, such as performance status, cancer anorexia, cachexia, dyspnea, and delirium have been identified, and several prognostic scores have been developed. These scores include the Palliative Prognostic (PaP) Score, Palliative Prognostic Index (PPI), Objective Prognostic Score (OPS), Japan Palliative Oncology Study Prognostic Index (JPOS-PI) and Prognosis Palliative Care Study (PiPS) predictor models.^[@ref1]-[@ref7])^ Because these conventional prognostic scores include subjective or categorical variables (e.g., clinical judgement, anorexia, or edema) for which the intensity or severity is less quantifiable, there can be limitations for more objective evaluation. The aim of this study was to identify, from routine laboratory blood examination, prognostic factors for 30-day mortality and to develop an objective additional prognostic model in terminally ill cancer patients.

PATIENTS AND METHODS
====================

Study design and patient population
-----------------------------------

This retrospective study attempted to identify prognostic factors for 30-day mortality based on routine blood examination results for terminally ill cancer patients and to examine the internal validity of a laboratory test-based prognostic model. Between April 2006 and March 2014, a total of 1,766 terminally ill cancer patients with disseminated malignancy, who were no longer subject to specific anticancer therapy, were admitted to our hospice. Of these, 458 patients were excluded from this study due to a lack of comprehensive blood data. A total of 1308 patients were included in this study. Patients were divided into an investigation group (n=761), admitted to our hospice between April 2006 and March 2011, and a validation group (n=547), admitted to our hospice between April 2011 and March 2014. Data were obtained from the final blood test before hospice discharge in each patient and included C-reactive protein (CRP), serum albumin (Alb), total bilirubin, aspartate aminotransferase (AST), alanine aminotransferase (ALT), blood urea nitrogen (BUN), creatinine, estimated glomerular filtration rate (eGFR), white blood cell (WBC) count, basophil percentage, eosinophil percentage (Eosino), neutrophil percentage, lymphocyte count, neutrophil-to-lymphocyte ratio (N/L), red blood cell (RBC) counts, hemoglobin (Hb) level, hematocrit (Ht), mean corpuscular volume (MCV), red cell distribution width (RDW), and platelet (Plt) count. The eGFR was calculated based on the serum creatinine level according to the equation recommended by the Japanese Society of Nephrology.^[@ref8])^

Our hospice care involves medical care, pain management, drug administration and infusion to reduce patients' physical and psychological discomfort. In April 2013, the number of hospice beds was reduced from 25 to 20; however, there was no change in general care management or hospitalization criteria that included withdrawing life-sustaining treatment and cytoreductive therapy. There is no hospice standard for performing blood tests. Our hospice physicians usually perform blood test, if the blood test results can change the management of patient's symptom.

The study protocol was approved by the Institutional Review Board of our hospital (approval reference number: 2016.082), which waived the requirement for informed consent owing to the retrospective nature of the study.

Statistical Analysis
--------------------

Continuous variables, expressed as the median (interquartile range (IQR)), were compared using the Mann-Whitney U test. Differences in categorical data were compared using the chi-squared test. The Kaplan-Meier method was used to estimate survival curves, and the log-rank test was used to evaluate survival differences between groups. Follow-up information to hospice discharge was compiled for all patients, and survival was calculated from the day the final blood test was performed before hospice discharge until the date of hospice discharge. When the survival was calculated, patients who left the hospice alive were censored.

For univariate analyses in the investigation group, receiver operating characteristic (ROC) analysis was performed, and the area under each ROC curve (AUC) was calculated to assess the prognostic value for 30-day survival. In ROC analysis, the optimal cutoff values were determined to be the point where the vertical distance between the ROC curve and the diagonal line was maximal.

Multiple logistic regression analysis was performed using 30-day survival (yes/no) as the dependent variable.^[@ref9])^ Variables with p\<0.05 by univariate analysis were entered into the equation to identify significant independent prognostic factors of 30-day mortality, while AST and ALT were integrated to ALT, because they had a close relationship, and the AUC of ALT was larger than that of ALT. Similarly, red blood cell count, hemoglobin, and hematocrit were integrated to hemoglobin. In the validation group, the predictive factors identified from the investigation group were examined for validity. Statistical analyses were performed using JMP software (version 10.0 for Windows; SAS Institute Inc., Cary, NC, USA). Significance was set at a level of p \<0.05.

RESULTS
=======

Patient demographics
--------------------

Patient demographics are presented in [Table 1](#table1){ref-type="table"}. The most common sites of primary malignancy were the respiratory, gastrointestinal, and hepatobiliary systems. Although there were statistically significant differences in albumin, ALT, WBC, lymphocyte count, MCV and Plt between the investigation and validation groups, there were no significant differences in age and sex. The mean duration between blood examination and hospice discharge in the investigation group was significantly longer than that in the validation group (24 days vs. 23 days, respectively); the 30-day survival of the investigation and validation group was 42.3% and 39.0%, respectively.

###### 

Patient demographics

  --------------------------------------------------------------------------------------------------------------------------------------------------------------
                                                                             Investigation group\   Validation group\      p-value                  
                                                                             (n=761)                (n=547)                                         
  -------------------------------------------------------------------------- ---------------------- ---------------------- -------------- --------- ------------
  Age                                                                        73 (65--80)            73 (65--79)            0.5575                   

  Sex (Male : Female)                                                        479 : 282              342 : 205              0.8766                   

  Site of primary malignancy                                                                                                                        **0.0484**

  Respiratory (including lung, pleura)                                       298                    (39.2%)                208            (38.0%)   

  Gastrointestinal                                                           225                    (29.6%)                142            (26.0%)   

  Hepatobiliary                                                              105                    (13.8%)                64             (11.7%)   

  Breast                                                                     22                     (2.9%)                 19             (3.5%)    

  Bladder, kidney, urinary tracts                                            21                     (2.8%)                 22             (4.0%)    

  Hematological                                                              20                     (2.6%)                 20             (3.7%)    

  Oral cavity                                                                16                     (2.1%)                 8              (1.5%)    

  Pharyngolarynx                                                             9                      (1.2%)                 11             (2.0%)    

  Female genital organs (including ovary, uterus)                            9                      (1.2%)                 21             (3.8%)    

  Head and neck (including thyroid, parotid gland)                           9                      (1.2%)                 6              (1.1%)    

  Male genital organs (including prostate)                                   8                      (1.1%)                 11             (2.0%)    

  Skin                                                                       6                      (0.8%)                 2              (0.4%)    

  Brain                                                                      3                      (0.4%)                 1              (0.2%)    

  Others                                                                     10                     (1.3%)                 12             (2.2%)    

  Blood examination data                                                                                                                            

  C-reactive protein (mg/dL)                                                 5.5 (1.9--10.6)        5.2 (2.1--10.9)        0.9725                   

  Albumin (g/dL)                                                             2.6 (2.2--3.1)         2.8 (2.4--3.2)         **0.0019**               

  Total bilirubin (mg/dL)                                                    0.6 (0.4--1.1)         0.6 (0.5--1.0)         0.7574                   

  Aspartate aminotransferase (AST) (IU/L)                                    30 (20--53)            27 (19--51)            0.2076                   

  Alanine aminotransferase (ALT) (IU/L)                                      19 (13--37)            17 (11--33)            **0.0095**               

  Blood urea nitrogen (BUN) (mg/dL)                                          20 (14--30)            20 (15--32)            0.1522                   

  Creatinine                                                                 0.74 (0.57--1.03)      0.75 (0.55--1.12)      0.6237                   

  Estimated glomerular filtration rate (eGFR) (ml/min/1.73 m^2^)             71 (48--96)            70 (46--96)            0.5508                   

  White blood cell count (×10^3^/μL)                                         9.0 (6.4--13.1)        8.4 (6.2--11.6)        **0.0251**               

  Basophil (%)                                                               0.3 (0.1--0.5)         0.3 (0.1--0.6)         0.0567                   

  Eosinophil (%)                                                             0.6 (0.2--1.6          0.4 (0.1--1.5)         **0.0333**               

  Neutrophil (%)                                                             80.7 (72.2--87.2)      81.7 (73.5--88.3)      0.1251                   

  Lymphocyte count (×10^3^/μL)                                               0.924 (0.591--1.344)   0.804 (0.531--1.165)   0.0003                   

  Neutrophil-to-lymphocyte ratio (N/L)                                       7.6 (4.5--13.8)        8.3 (4.8--15.2)        0.0644                   

  Red blood cell count (×10^6^/μL)                                           3.33 (2.82--3.84)      3.32 (2.71--3.81)      0.4353                   

  Hemoglobin (g/dL)                                                          10.2 (8.8--11.7)       10.2 (8.5--11.6)       0.3058                   

  Hematocrit (%)                                                             30.3 (26.0--34.6)      30.7 (25.8--34.9)      0.8400                   

  Mean corpuscular volume (MCV) (fℓ)                                         91.8 (87.2--96.8)      92.8 (88.4--97.9)      **0.0102**               

  Red cell distribution width (RDW)                                          16.6 (15.2--18.8)      16.7 (15.0--18.8)      0.9475                   

  Platelet count (×10^3^/μL)                                                 257 (183--352)         229 (158--308)         **\<0.0001**             

  Hospice discharge (Dead : Alive)                                           740 : 21               515 : 32               **0.0052**               

  Length of hospice stay (days)                                              17 (7--38)             19 (8--39)             0.4105                   

  Duration between the last blood examination and hospice discharge (days)   24 (11--48)            23 (9--42)             **0.0242**               

  Median survival (days) after the last blood examination                    24                     23                     0.3792                   

  30-day survival after the last blood examination                           42.3%                  39.0%                  0.3792                   
  --------------------------------------------------------------------------------------------------------------------------------------------------------------

Continuous variables are expressed as the median (interquartile range), and categorical variables are described as numbers (percentages). Bold values indicate statistical significance (p\<0.05).

Identification of significant independent prognostic factors for predicting 30-day survival
-------------------------------------------------------------------------------------------

The AUC and optimal cutoff value for the 20 blood test data used to estimate 30-day survival are presented in [Table 2](#table2){ref-type="table"}. Univariate analyses of survival revealed that cutoff values of the 19 variables were statistically discriminative. Multivariate analysis showed that the following ten indices were significant independent prognostic factors for 30-day survival ([Table 2](#table2){ref-type="table"}): CRP ≥5.4 mg/dL, Alb \<2.8 g/dL, BUN ≥21 mg/dL, WBC ≥8.600 × 10^3^/μL, Eosino \<0.8%, N/L ≥11.1, Hb ≥ 13.2 g/dL, MCV ≥ 93.7 fL, RDW ≥ 16, and Plt \< 159 × 10^3^/μL had odds ratios for 30-day mortality between 1.47 and 2.54.

###### 

Predictive value for 30-day survival of blood test data

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  **Blood test data**                               AUC      Optimal cut-off value   Univariate analysis   Multivariate analysis                                                
  ------------------------------------------------- -------- ----------------------- --------------------- ----------------------- ------- -------------- ------ -------------- ------------
  **C-reactive protein**                            0.6752   5.4 mg/dL               ≧5.4                  385                     29.4%   **\<0.0001**   1.86   1.30 -- 2.67   **0.0007**

                                                             \<5.4                   376                   55.5%                   1                                            

  **Albumin**                                       0.6275   2.8 g/dL                ≧2.8                  294                     56.0%   **\<0.0001**   1                     **0.0006**

                                                             \<2.8                   467                   33.7%                   1.9     1.31 -- 2.76                         

  **Total bilirubin**                               0.5909   1.3 mg/dL               ≧1.3                  151                     23.8%   **\<0.0001**   1.55   0.93 -- 2.62   0.0953

                                                             \<1.3                   610                   46.8%                   1                                            

  **Aspartate**\                                    0.5783   47 IU/L                 ≧47                   218                     47.3%   **\<0.0001**                         
  **aminotransferase (AST)**                                                                                                                                                    

                                                             \<47                    243                   31.2%                                                                

  **Alanine aminotransferase (ALT)**                0.6141   19 IU/L                 ≧19                   401                     33.5%   **\<0.0001**   1.44   0.99 -- 2.29   0.0511

                                                             \<19                    360                   54.0%                   1                                            

  **Blood urea nitrogen (BUN)**                     0.6782   21 mg/dL                ≧21                   354                     27.8%   **\<0.0001**   1.98   1.33 -- 2.95   **0.0007**

                                                             \<21                    407                   54.8%                   1                                            

  **Creatinine**                                    0.5481   1.09 mg/dL              ≧1.09                 168                     25.8%   **\<0.0001**   1.80   0.86 -- 3.79   0.1172

                                                                                     \<1.09                593                     46.9%   1                                    

  **Estimated glomerular filtration rate (eGFR)**   0.5577   45 ml/min/ 1.73 m^2^    ≧45                   596                     46.6%   **\<0.0001**   1                     0.5568

                                                             \<45                    165                   27.3%                   1.25    0.60 -- 2.64                         

  **White blood cell count**                        0.6589   8.600 × 10^3^/μL        ≧8.600                417                     30.2%   **\<0.0001**   1.47   1.00 -- 2.15   **0.0495**

                                                             \<8.600                 344                   57.0%                   1                                            

  **Basophil**                                      0.5940   0.1 %                   ≧0.1                  605                     46.6%   **\<0.0001**   1                     0.4266

                                                             \<0.1                   156                   25.4%                   1.22    0.75 -- 2.00                         

  **Eosinophil**                                    0.6524   0.8 %                   ≧0.8                  304                     59.0%   **\<0.0001**   1                     **0.0349**

                                                             \<0.8                   457                   32.7%                   1.50    1.03 -- 2.18                         

  **Neutrophil**                                    0.6551   83.7 %                  ≧83.7                 300                     25.9%   **\<0.0001**   1.02   0.59 -- 1.78   0.9329

                                                             \<83.7                  461                   53.0%                   1                                            

  **Lymphocyte count**                              0.4352   2.218 × 10^3^/μL        ≧2.218 × 10^3^        60                      26.7%   **0.0019**     1.84   0.92 -- 3.81   0.0847

                                                             \<2.218 × 10^3^         701                   43.6%                   1                                            

  **Neutrophil-to-lymphocyte ratio (N/L)**          0.6684   11.1                    ≧11.1                 257                     22.5%   **\<0.0001**   2.23   1.29 -- 3.91   **0.0043**

                                                             \<11.1                  504                   54.3%                   1                                            

  **Red blood cell count**                          0.5163   4.17 × 10^6^/μL         ≧4.17 × 10^6^         96                      32.9%   **0.0309**                           

                                                             ≧4.17 × 10^6^           665                   43.6%                                                                

  **Hemoglobin**                                    0.5016   13.2 g/dL               ≧13.2                 51                      30.4%   **0.0101**     2.54   1.34 --4.96    **0.0041**

                                                             \< 13.2                 687                   43.5%                                                                

  **Hematocrit**                                    0.5011   34.70%                  ≧34.7                 186                     37.4%   0.0749                               

                                                             \<34.7                  575                   43.8%                                                                

  **Mean corpuscular volume (MCV)**                 0.5433   93.7 fL                 ≧93.7                 295                     49.9%   **\<0.0001**   1                     **0.0001**

                                                             \<93.7                  466                   37.5%                   2.07    1.43 -- 3.02                         

  **Red cell distribution width (RDW)**             0.5871   16                      ≧16                   474                     35.4%   **0.0027**     1.71   1.19 -- 2.46   **0.0034**

                                                             \<16                    287                   53.4%                   1                                            

  **Platelet count**                                0.5473   159 × 10^3^/μL          ≧159 × 10^3^          605                     45.9%   **\<0.0001**   1                     **0.0007**

                                                             \<159 × 10^3^           156                   28.2%                   2.19    1.39 -- 3.50                         
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Bold values indicate statistical significance (p\<0.05).

Prognostication by laboratory prognostic score (LPS)
----------------------------------------------------

To develop a scoring system for 30-day mortality, laboratory prognostic score (LPS) was calculated by the sum of indices among the ten variables. In the investigation group, the median survival was decreased according to the LPS ([Figure 1(A)](#fig1){ref-type="fig"}). [Figure 2(A)](#fig2){ref-type="fig"} shows the number of patients with each LPS and 30-day survival, which was decreased from 100% to 0% according to the LPS between 0 and 10. The LPS ROC curve is shown in [Figure 3(A)](#fig3){ref-type="fig"}; the AUC was 0.7901 at the optimal cutoff value of LPS 5. LPS 5 predicted death within 30 days, with a sensitivity of 85%, a specificity of 55%, a positive predictive value (PPV) of 72%, and a negative predictive value (NPV) of 74% ([Table 3](#table3){ref-type="table"}).

![Median survival (solid line) and 25% and 75% percentiles (dotted lines) of patients with each laboratory prognostic score (LPS).\
(A) Investigation group (n=761), (B) Validation group (n=547).](2186-3326-80-0571-g001){#fig1}

![Number of patients with each laboratory prognostic score (LPS) (primary graph, presented as bars) and 30-day survival (secondary graph, presented as a line)\
(A) Investigation group (n=761), (B) Validation group (n=547).](2186-3326-80-0571-g002){#fig2}

![Receiver operating characteristic curve of laboratory prognostic score (LPS)\
(A) Investigation group (n=761), (B) Validation group (n=547).](2186-3326-80-0571-g003){#fig3}

###### 

Thirty-day survival and predictive value for 30-day mortality classified by laboratory prognostic score (LPS) comprised of 10 blood indices (CRP ≥5.4 mg/dL, Alb \<2.8 g/dL, BUN ≥21 mg/dL, WBC ≥8.600 × 10^3^/μL, Eosino \<0.8%, N/L ≥11.1, Hb ≥13.2 g/dL, MCV ≥93.7 fL, RDW ≥16, and Plt \<159×10^3^/μL).

  ---------------------------------------------------------------------------------------------------------------------
                 Investigation group                                                                           
  -------------- --------------------- ------- ------- ------- ------- ------- ------- ------- ------- ------- --------
  Number of\     7                     32      85      117     125     129     118     92      49      5       2
  patients                                                                                                     

  30-day\        100%                  88%     78%     65%     47%     35%     22%     15%     4%      0%      0%
  survival\                                                                                                    
  (%)                                                                                                          

  Sensitivity\   100%                  100%    100%    99%     94%     85%     70%     51%     30%     12%     1%
  (%)                                                                                                          

  Specificity\   0%                    2%      2%      11%     31%     55%     73%     87%     95%     99%     100%
  (%)                                                                                                          

  Positive\      57%                   58%     58%     60%     65%     72%     78%     84%     89%     96%     100%
  predictive\                                                                                                  
  value (%)                                                                                                    

  Negative\      --                    100%    78%     85%     81%     74%     65%     57%     50%     46%     43%
  predictive\                                                                                                  
  value (%)                                                                                                    

                                                                                                               

                 Validation group                                                                              

  **LPS**        **0**                 **1**   **2**   **3**   **4**   **5**   **6**   **7**   **8**   **9**   **10**

  Number of\     9                     24      55      79      98      99      88      62      25      7       1
  patients                                                                                                     

  30-day\        78%                   72%     72%     52%     46%     28%     23%     21%     4%      14%     0%
  survival\                                                                                                    
  (%)                                                                                                          

  Sensitivity\   100%                  99%     99%     98%     93%     82%     66%     44%     24%     9%      2%
  (%)                                                                                                          

  Specificity\   0%                    3%      3%      12%     30%     50%     71%     83%     93%     99%     100%
  (%)                                                                                                          

  Positive\      60%                   61%     61%     63%     67%     71%     77%     80%     84%     94%     86%
  predictive\                                                                                                  
  value (%)                                                                                                    

  Negative\      --                    78%     70%     76%     74%     64%     58%     50%     45%     42%     40%
  predictive\                                                                                                  
  value (%)                                                                                                    
  ---------------------------------------------------------------------------------------------------------------------

Validation of LPS for predicting 30-day mortality
-------------------------------------------------

In the validation group, the median survival was decreased according to the LPS ([Figure 1(B)](#fig1){ref-type="fig"}). [Figure 2(B)](#fig2){ref-type="fig"} shows the number of patients with each LPS and 30-day survival, which was decreased from 78% to 0% according to the LPS between 0 and 10. The LPS ROC curve is shown in [Figure 3(B)](#fig3){ref-type="fig"}; the AUC was 0.7337 at the optimal cutoff value of LPS 5. LPS 5 predicted death within 30 days, with a sensitivity of 82%, a specificity of 50%, a PPV of 71%, and a NPV of 64% ([Table 3](#table3){ref-type="table"}).

DISCUSSION
==========

The present study revealed that ten blood indices were independent prognostic factors for 30-day mortality of terminally ill cancer patients. The LPS comprising these ten indices showed acceptable accuracy, which was comparable to those of the validation group.

Conventional prognostic scores previously reported in the literature are based on physical signs, symptoms, and psychological factors with/without data from laboratory blood tests.^[@ref1]-[@ref7],[@ref10]-[@ref11])^ Those prognostic scores are universally available and useful for terminal care of cancer patients; however, their potential limitation is the inclusion of subjective or categorical variables such as physician's judgment (i.e., clinical prediction of survival), dyspnea, anorexia, edema, pleural effusion, or consciousness, for which the intensity or severity is less quantifiable; and consequently, there can be limitations for more objective evaluation.^[@ref12])^ [Table 4](#table4){ref-type="table"} shows reported predictive values of several prognostic scores for terminally ill cancer patients.^[@ref4]-[@ref5],[@ref13]-[@ref14])^ The predictive value of the LPS was comparable to those of conventional prognostic scores, although the median survivals were different among the studies (22--27 days).

###### 

Comparison of the predictive values among conventional prognostic scores and laboratory prognostic score

  No.                         1                                      2                                             3                                       4            5                         6
  --------------------------- -------------------------------------- --------------------------------------------- --------------------------------------- ------------ ------------------------- ---------------------------------------
  Predicting Model            **Objective Prognostic Score (OPS)**   **Palliative Prognostic Score (PaP Score)**   **Palliative Prognostic Index (PPI)**                                          **Laboratory Prognostic Score (LPS)**
  Year                        2010                                   2012                                          1999                                    2012         2017                      
  Author                      Suh SY                                 Maltoni M                                     Morita T                                Maltoni M    Yamada T                  Kawai N
  Country                     South Korea                            Italy                                         Japan                                   Italy        Japan                     Japan
  Number of patients          185                                    549                                           150                                     549          892                       761
  Setting                     inpatient                              in hospice                                    in hospice                              in hospice   in palliative care unit   in hospice
  Median survival             26 days                                22 days                                       27 days                                 22 days      25 days                   24 days
  30-day survival             nd                                     nd                                            nd                                      nd           nd                        42%
  3-week survival             nd                                     nd                                            63%                                     nd           nd                        57%
  Score range                 0--8                                   0--17.5                                       0--15.0                                 0--15.0      0--15.0                   0--10
  Mortality prediction        3 weeks                                30 days                                       3 weeks                                 30 days      3 weeks                   30 days
  Cutoff value                OPS: 3                                 PaP Score: 5                                  PPI: 6.0                                PPI: 4.0     PPI: 6.0                  LPS: 5
  Sensitivity                 75 %                                   92 %                                          75 %                                    85 %         71 %                      85 %
  Specificity                 77 %                                   58 %                                          84 %                                    54 %         67 %                      55 %
  Positive Predictive Value   42 %                                   76 %                                          73 %                                    73 %         63 %                      72 %
  Negative Predictive Value   79 %                                   82 %                                          85 %                                    70 %         75 %                      74 %

nd: not described

Many studies have found several biomarkers to have prognostic value for terminally ill cancer patients: lymphocyte count, WBC, lactate dehydrogenase, BUN, Hb, CRP, Alb, and creatinine.^[@ref2],[@ref5]-[@ref6],[@ref15]-[@ref18])^ The current study implies that the sum of blood indices of the ten indices (CRP ≥5.4 mg/dL, Alb \<2.8 g/dL, BUN ≥21 mg/dL, WBC ≥8.600 × 10^3^/μL, Eosino \<0.8%, N/L ≥11.1, Hb ≥ 13.2 g/dL, MCV ≥ 93.7 fL, RDW ≥ 16, and Plt \< 159×10^3^/μL) has an acceptable prognostic value. An elevated CRP, WBC and N/L suggest inflammation or overproduction of cytokine produced by malignant tumor, while a decreased Alb implies malnutrition. An increased BUN suggests dehydration, gastrointestinal bleeding, or impaired renal function. Decreased immune status is suggested by an elevated N/L. A decreased platelet count implies bone marrow suppression or bleeding tendency. An elevated Hb suggests dehydration.

To the best of our knowledge, this is the first study showing a significant prognostic value of eosinophil percentage, MCV, and RDW in terminally ill cancer patients. Eosinophils are a component of the innate immune system and have a variety of functions.^[@ref19])^ Several studies have reported a lower eosinophil count as a worse prognostic marker in patients with acute heart failure, chronic obstructive pulmonary disease, critical medical illness, and bacteremia.^[@ref20]-[@ref23])^ The MCV indicates the volume of RBC and is frequently used for the diagnosis of megaloblastic or iron-deficiency anemia. A high MCV was associated with worse outcomes in patients with coronary artery disease and renal failure.^[@ref24]-[@ref25])^ The RDW is a measure of the range of variation of RBC volume and has traditionally been used to differentiate various types of anemia.^[@ref26])^ The evidence associating RDW with a higher risk of mortality has been reported in patients with coronary disease, heart failure, acute cerebral infarction, and septic shock.^[@ref27]-[@ref30])^

To improve the discriminative ability of LPS, we developed a scoring system in which each one of ten categories was assigned various points based on the logarithm of odds ratio. The AUC of this model was 0.7528, which was lower than the AUC of the original LPS model developed from the sum of indices. We, therefore, adopted the original LPS model.

We acknowledge that our study has several limitations. First, this study was retrospective and was conducted at a single hospice; thus, the results could not be extrapolated to other palliative care settings (e.g., hospital palliative care, home palliative care, and patients undergoing antiblastic therapy). Second, venipuncture is necessary for LPS determination. It may not be easy for physicians to perform invasive procedures on frail patients. Third, the timing of blood examination was not specifically planned for prognostication but mostly for symptom management, and the last day at which blood samples were collected was chosen among several days for analyzing 30-mortality. Scheduled blood sampling should have been performed for accurate prognostic estimation; however, this could not be done because of the retrospective nature of the study. Fourth, this study included patients with hematological malignancy. Such patients often have blood disorder even in the early phase of disease; therefore, LPS may be less prognostic for patients with hematological malignancy. Fifth, this study did not compare the prognostic values between conventional prognostic scores and LPS in each patient. The comparison may reveal the significance of LPS; however, it was not performed due to the limited number of patients who were evaluated by conventional prognostic scores. Sixth, although this study revealed ten indices (CRP ≥5.4 mg/dL, Alb \<2.8 g/dL, BUN ≥21 mg/dL, WBC ≥8.600 × 10^3^/μL, Eosino \<0.8%, N/L ≥11.1, Hb ≥ 13.2 g/dL, MCV ≥ 93.7 fL, RDW ≥ 16, and Plt \< 159 × 10^3^/μL) that have an acceptable prognostic value in terminally ill cancer patients, we could not provide sufficient meaning in some indices.

The strength of this study was the large number of patients and comprehensive analysis of routine blood tests. The predictive value of LPS was comparable to that of conventional prognostic scores. Although the estimation of 30-day mortality by LPS requires venipuncture, it was objective and easily understandable. The LPS can be used in combination with physical signs and symptoms to improve prognostication. Future studies should focus on validating our results and estimating more accurately the short-term mortality of terminally ill cancer patients.
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